We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Hologic Inc | NASDAQ:HOLX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 75.91 | 77.50 | 78.58 | 0 | 12:00:11 |
BEDFORD, Mass., Aug. 6, 2014 /CNW/ -- Hologic, Inc. today announced that Health Canada granted a medical device license for Horizon, a new DXA (dual-energy x-ray absorptiometry) imaging platform that assists in the assessment of three critical health problems - osteoporosis, cardiovascular disease, and obesity. Horizon was launched in the U.S. and other international markets in 2013.
The Horizon DXA platform is designed to offer improved precision, stability and throughput over current products. New, clinically relevant built-in enhancements include a high-resolution multi-element detector array with ceramic detector technology for improved bone mapping and image quality; a high-frequency pulsing power supply that offers greater system stability and future flexibility; and a filter drum to support future development initiatives. Built on Hologic proprietary technologies, Horizon offers expanded technical capabilities, workflow efficiencies and improved design components to meet clinician needs now and into the future.
The Hologic Horizon DXA platform offers the following features:
"Since its introduction in 2013, Hologic's Horizon DXA platform has set a new standard for image quality and operational efficiency," said Peter J. Valenti III, Hologic Division President, Breast and Skeletal Health Solutions. "Horizon combines a wealth of proprietary, advanced technologies that provide clinicians with the most accurate diagnostic information available. Moving forward we remain committed to providing technologies that will differentiate Hologic from our competitors and help women and men throughout the world lead healthier, stronger lives."
The global impact of osteoporosis, cardiovascular disease, and obesity-related problems is serious and costly. It is estimated one in two women and one in four men over age 50 will have an osteoporosis-related fracture during their lifetime.1 Approximately 17 million people die from cardiovascular disease each year.2 The incidence of obesity has increased 82% in the past 20 years3 and it is estimated that 2.8 million people die each year from complications related to this disease.4 Together, these health issues represent a significant cost to national healthcare systems and impact millions of lives.
About Hologic, Inc.:
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems, and surgical products, with an emphasis on serving the healthcare needs of women. The Company operates four core business units focused on diagnostics, breast health, GYN surgical and skeletal health. With a comprehensive suite of technologies and a robust research and development program, Hologic is committed to improving lives. The Company is headquartered in Massachusetts. For more information, visit www.hologic.com.
Hologic, Advanced Body Composition, Horizon, Instant Vertebral Assessment, and associated logos are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.
Forward-looking Statement Disclaimer:
This Media Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic's Horizon platform. There can be no assurance the system will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of the system can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.
Contacts: |
|
Marianne McMorrow |
Jim Culley |
Manager, Corporate Communications |
Senior Director, Corporate Communications |
Tel: +1 (781) 999-7723 |
Tel: +1 (781) 999-7463 |
marianne.mcmorrow@hologic.com |
jim.culley@hologic.com |
1 Handout on Health: Osteoporosis, Riggs and Melton 1995
2 World Health Organization (WHO). http://www.who.int/cardiovascular_diseases/resources/atlas/en/
3 The Lancet, Volume 380, Issue 9859, Pages 2053 - 2054, 15 December 2012 >doi:10.1016/S0140-6736(12)62133-3
4 World Health Organization (WHO). http://www.who.int/features/factfiles/obesity/facts/en/index1.html
SOURCE Hologic, Inc.
Copyright 2014 Canada NewsWire
1 Year Hologic Chart |
1 Month Hologic Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions